title: CYP2E1 RsaI/PstI polymorphisms contributed to oral cancer susceptibility: a meta-analysis.
abstract: Several studies have investigated the associations between CYP2E1 RsaI/PstI polymorphisms and oral cancer risk, but results have been inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. PubMed and China National Knowledge Infrastructure (CNKI) searches were carried out for relevant studies published before September 2014. Meta-analysis was performed with the Stata, version 11.0. A total of 14 case control studies, including 1,962 cases and 3,271 controls, were selected. Overall, significant association was found between the CYP2E1 RsaI/PstI polymorphisms and oral cancer risk (for c1c1 vs. c1c2, OR=0.72, 95% CI=0.56-0.91; for c1c1 vs. c2c2, OR=0.45, 95% CI=0.25-0.82), while not for the dominant model (c1c1 vs. c1c2+c2c2, OR=0.84, 95% CI=0.69-1.01). In the subgroup analysis by ethnicity, statistically significant association was found in Caucasian, East Asian and South Asian. This meta-analysis suggests that the CYP2E1 RsaI/PstI polymorphisms are a risk factor for developing oral cancer.
authors.affiliation: Department of Endodontics, The 2nd Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Department of Orthodontics, The 2nd Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Zhou
authors.affiliation: Department of Stomatology, Harbin Children's Hospital Harbin, Heilongjiang, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.affiliation: Department of Implantology, The 2nd Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
mesh_terms: D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D009062:Mouth Neoplasms / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic / Q000235:genetics*
chemical_list: D019392:Cytochrome P-450 CYP2E1
keywords: CYP2E1; meta-analysis; oral cancer; polymorphism
references.citation: Int J Cancer. 1999 Mar 1;80(5):685-8
references.pmid: 10048967
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2438-49
references.pmid: 21940907
references.citation: Asian Pac J Cancer Prev. 2011;12(6):1523-7
references.pmid: 22126492
references.citation: Int J Cancer. 1999 Nov 26;83(5):606-9
references.pmid: 10521794
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Psychiatry Res. 2004 Nov 30;129(1):39-44
references.pmid: 15572183
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):476-82
references.pmid: 15734975
references.citation: J Oral Pathol Med. 2006 Jan;35(1):11-8
references.pmid: 16393248
references.citation: Oral Oncol. 2006 Jul;42(6):632-7
references.pmid: 16488179
references.citation: Head Neck. 2006 Sep;28(9):819-26
references.pmid: 16721740
references.citation: J Natl Cancer Inst. 2007 May 16;99(10):777-89
references.pmid: 17505073
references.citation: Int J Cancer. 2000 Sep 1;87(5):734-40
references.pmid: 10925369
references.citation: Oral Oncol. 2001 Jul;37(5):437-45
references.pmid: 11377232
references.citation: Int J Cancer. 2002 Feb 1;97(4):526-30
references.pmid: 11802217
references.citation: Genet Med. 2002 Mar-Apr;4(2):45-61
references.pmid: 11882781
references.citation: Br J Cancer. 1982 Dec;46(6):856-69
references.pmid: 6960923
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Anticancer Res. 1991 Jul-Aug;11(4):1477-84
references.pmid: 1746905
references.citation: J Biochem. 1991 Oct;110(4):559-65
references.pmid: 1778977
references.citation: J Biochem. 1994 Aug;116(2):321-6
references.pmid: 7529759
references.citation: Physiol Rev. 1997 Apr;77(2):517-44
references.pmid: 9114822
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Ann Intern Med. 1997 Nov 1;127(9):820-6
references.pmid: 9382404
references.citation: Head Neck. 2007 Jul;29(7):682-99
references.pmid: 17274053
references.citation: Pharmacogenomics. 2008 May;9(5):551-60
references.pmid: 18466102
references.citation: Head Neck. 2008 Sep;30(9):1139-47
references.pmid: 18642288
references.citation: Oral Oncol. 2009 Apr-May;45(4-5):309-16
references.pmid: 18804401
references.citation: Oral Oncol. 2010 Jan;46(1):9-13
references.pmid: 19896412
references.citation: BMC Cancer. 2010;10:575
references.pmid: 20969746
references.citation: Mol Biol Rep. 2011 Apr;38(4):2409-16
references.pmid: 21076874
references.citation: Oral Oncol. 2011 Sep;47(9):866-72
references.pmid: 21741876
references.citation: Otolaryngol Head Neck Surg. 2011 Oct;145(4):586-93
references.pmid: 21705789
references.citation: Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):901-5
references.pmid: 9367063